TY  - JOUR
Y1  - 2019/06//
TI  - Under crossfire: thromboembolic risk in systemic lupus erythematosus
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
ID  - discovery10063289
EP  - 952
N2  - Cerebral and cardiovascular ischaemic events are frequent complications of SLE and constitute primary causes of permanent damage. However, the pathogenic determinants of an increased thromboembolic risk in patients with SLE are only partially understood. Atherosclerosis constitutes fertile soil for the development of thrombosis and shows disproportionately high prevalence and progression rates in patients with SLE. aPLs are independent risk factors for acute thrombosis but can also prompt long-term vascular inflammation. Aberrant interactions among immune cells and dysfunctions in the deployment of the coagulation cascade have historically been less explored in SLE, but recent evidence suggests they can also play a critical role at the crossroads between inflammation and haemostasis. In this review we discuss how different prothrombotic mechanisms can be prompted by and synergize with SLE-specific pathogenic events and speculate about novel potential directions for research and drug development.
VL  - 58
UR  - https://doi.org/10.1093/rheumatology/key307
A1  - Ramirez, GA
A1  - Efthymiou, M
A1  - Isenberg, DA
A1  - Cohen, H
SN  - 1462-0332
SP  - 940
IS  - 6
KW  - antiphospholipid antibodies
KW  -  atherosclerosis
KW  -  cardiovascular risk
KW  -  coagulation
KW  -  innate immunity
KW  -  ischaemia
KW  -  protein C
KW  -  systemic lupus erythematosus
KW  -  thromboembolism
KW  -  thrombosis
JF  - Rheumatology
AV  - public
ER  -